前立腺肥大症に対するSH 582の使用経験 --estrogen療法との比較--

Abstract

Twenty-five cases of prostatic hypertrophy aging from 56 to 84 were treated with SH 582 over a period ranging from 10 days to 12 months at weekly doses of 300 mg to 900 mg up to a total of 1200 mg to 27000 mg. Clinical symptoms were improved in 19 (76 %) of 25 cases. Retention of urine was greatly or moderately improved in 16 cases (64 %), and unchanged in 9 cases (36 %), which were almost equal to those obtained with estrogen. Palpation of the prostate demonstrated a mild reduction in size in 10 cases (40 %), but histological investigation revealed no clear evidence of reduction in the size of adenoma. Cystourethrography performed in 11 cases were negative for any appreciable change due to administration of SH 582. Body weight was increased in 4 cases and decreased in 1 case. Pre-existing potency in 6 cases was decreased in 4 cases after administration. Hepatic function examined in 19 cases was within normal limits.